- Home
- IQV vs IR Comparison
IQV vs IR Comparison
Compare IQV & IR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IQV | IR |
|---|---|---|
| Founded | 1982 | 1859 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 32.9B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IQV | IR |
|---|---|---|
| Price | $168.96 | $70.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $227.13 | $96.00 |
| AVG Volume (30 Days) | 1.6M | ★ 3.6M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.10% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 1.61 | 0.49 |
| Revenue | ★ $9,739,000,000.00 | $2,375,400,000.00 |
| Revenue This Year | $6.77 | $7.10 |
| Revenue Next Year | $5.89 | $4.78 |
| P/E Ratio | ★ $104.62 | $143.08 |
| Revenue Growth | ★ 41.60 | 22.48 |
| 52 Week Low | $137.33 | $68.07 |
| 52 Week High | $247.05 | $100.96 |
Technical Indicators
Market Signals| Indicator | IQV | IR |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 36.38 |
| Support Level | $159.08 | N/A |
| Resistance Level | $172.80 | $81.53 |
| Average True Range (ATR) | 7.14 | 1.96 |
| MACD | -0.19 | -0.24 |
| Stochastic Oscillator | 46.88 | 23.47 |
Price Performance
Historical ComparisonAbout IQV IQVIA Holdings Inc.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
About IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.7 billion in revenue in 2025.